• Explore /
  • Poster
  • / Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (<em>MLL</em>)-rearrangement (r) or nucleophosmin 1 (<em>NPM1</em>) mutation (m).

Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (MLL)-rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m).

Abstract Video & Slides Poster

Authors

null

Naval Guastad Daver

Department of Leukemia, MD Anderson Cancer Center, Houston, TX

Naval Guastad Daver , John Affinito , Hongliang Cai , Hanna Dobrowolska , Ken Eguchi , Zijing Zhang , Jay Stoudemire , Akinobu Watanabe , Pablo Martinez , Philip Komarnitsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT04988555

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7066)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7066

Abstract #

TPS7066

Poster Bd #

295b

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.

Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.

First Author: Justin M. Watts

First Author: Roger Li

First Author: Eileen M. O'Reilly

First Author: Junji Furuse